The Oregon Department of Consumer and Business Services would step in if a drug exceeded $10,000 or had cost increases greater than 3.4 percent. State regulators would index a price according to what other countries have negotiated for the drugs. Consumers would also see a cap on costs that they pay out-of-pocket.
Rep. Rob Nosse, D-Portland, touted his aggressive and innovative approach to tackling uncontrolled pharmaceutical costs on Thursday, calling on Oregon to lead where Congress has failed and other state-based reforms have fallen short.